Benzinga | Sep 14, 2020 07:07AM EDT

Actinium Pharmaceuticals Announces Completion Of Planned Phase 1 Actimab-A CLAG-M Combination Trial In Patients With Relapsed/Refractory AML At Medical College Of Wisconsin

NEW YORK, Sept. 14, 2020 /PRNewswire/ --Actinium Pharmaceuticals, Inc. (NYSE:ATNM) (the "Company" or "Actinium") today provided an update on the Actimab-A CLAG-M combination Phase 1 trial being conducted at the Medical College of Wisconsin ("MCW") in patients with Relapsed or Refractory ("R/R") Acute Myeloid Leukemia (AML) age 18 and above who are fit for intensive therapy. All patients in the third dosing cohort, which was scheduled as the final cohort of the planned Phase 1 dose escalation trial, completed treatment with a 0.75 uCi/kg dose of Actimab-A followed by CLAG-M and have cleared their initial safety evaluation. Results from the planned portion of the Phase 1 trial including complete safety and efficacy data are expected to be presented by year end. Previously, it was reported that the second dose cohort demonstrated an 86% complete remission rate with 71% of patients achieving negative minimal residual disease status. Investigators at MCW have indicated that based on safety results thus far, they intend to expand the Phase 1 portion of the trial assuming FDA clearance.